Skip to main content

Advertisement

SpringerLink
Log in

The diagnostic value of SNpc using NM-MRI in Parkinson’s disease: meta-analysis

  • Review Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

A Correction to this article was published on 28 August 2019

This article has been updated

Abstract

The main purpose of this study was to systematically evaluate the accuracy of neuromelanin-sensitive magnetic resonance imaging (NM-MRI) in Parkinson’s disease (PD) diagnosis using a meta-analysis method. In PubMed, Web of Science, Embase, and Google Scholar, the literatures were searched for the diagnostic value of neuromelanin-sensitive magnetic resonance imaging in PD. The literatures were screened in the light of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Data analysis was processed by Stata 12.0 software to obtain meta-analysis, heterogeneity analysis, and publication bias. Meta-analysis results showed by using NM-MRI observed substantia nigra pars compacta (SNpc) on PD, the pooled diagnostic sensitivity and specificity were 0.82 (95% CI, 0.74–0.87) and 0.82 (95% CI, 0.73–0.89), respectively. And the pooled positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were 4.58 (95% CI, 3.08–6.82) and 0.22 (95% CI, 0.16–0.31), respectively. Moreover, subgroup analysis according to the measurement criteria of SNpc showed the SNpc volume should be used as good a marker for diagnosing PD. Finally, Fagan test demonstrated that when PLR was equal to 5, the posterior probability is significantly enhanced to 53%, compared with prior probability (20%). As for NLR (0.22), the prior probability is 20%, while the posterior probability remarkably dropped to 5%. In conclusion, SNpc signal detected by NM-MRI exhibited high sensitivity and specificity for diagnosis of PD, which was a high-performance imaging diagnostic method for PD. We recommend NM-MRI imaging technology to be widely used in Parkinson’s diagnosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Change history

  • 28 August 2019

    The above article was published online with incorrect author name. The right spelling should be Xiangming Wang instead of Xiangmin Wang. The correct name is presented here. The original article has been corrected.

References

  1. Sveinbjornsdottir S (2016) The clinical symptoms of Parkinson’s disease. J Neurochem 139(Suppl 1):318–324

    Article  CAS  Google Scholar 

  2. Niu XL, Liu L, Song ZX, Li Q, Wang ZH, Zhang JL, Li HH (2016) Prevalence of small intestinal bacterial overgrowth in Chinese patients with Parkinson’s disease. J Neural Transm (Vienna) 123(12):1381–1386

    Article  CAS  Google Scholar 

  3. Zou YM, Liu J, Tian ZY, Lu D, Zhou YY (2015) Systematic review of the prevalence and incidence of Parkinson’s disease in the People’s Republic of China. Neuropsychiatr Dis Treat 11:1467–1472

    Article  Google Scholar 

  4. Jankovic J (2008) Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79(4):368–376

    Article  CAS  Google Scholar 

  5. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 318(1):121–134

    Article  Google Scholar 

  6. Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV (2019) Blood-brain barrier: from physiology to disease and back. Physiol Rev 99(1):21–78

    Article  CAS  Google Scholar 

  7. Zucca FA, Vanna R, Cupaioli FA, Bellei C, de Palma A, di Silvestre D, Mauri P, Grassi S, Prinetti A, Casella L, Sulzer D, Zecca L (2018) Neuromelanin organelles are specialized autolysosomes that accumulate undegraded proteins and lipids in aging human brain and are likely involved in Parkinson’s disease. NPJ Parkinsons Dis 4:17

    Article  Google Scholar 

  8. Taniguchi D, Hatano T, Kamagata K, Okuzumi A, Oji Y, Mori A, Hori M, Aoki S, Hattori N (2018) Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson’s disease. Mov Disord 33(9):1488–1492

    Article  CAS  Google Scholar 

  9. Pavese N. 2018 Is neuromelanin the imaging biomarker for the early diagnosis of Parkinson’s disease that we were looking for? Parkinsonism Relat Disord.

  10. Rovini E, Maremmani C, Moschetti A, Esposito D, Cavallo F (2018) Comparative motor pre-clinical assessment in Parkinson’s disease using supervised machine learning approaches. Ann Biomed Eng 46(12):2057–2068

    Article  Google Scholar 

  11. Zhang Z, Wang J, Chen S, Liu C, Zhang B, Peng R, Sun S, Sun X, Zhao G, Qu Q, Li Y, Zhu S, Pan X, Shao M, Wang Y (2018) Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study. Transl Neurodegener 7:32

    Article  Google Scholar 

  12. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707 quiz 1837

    Article  Google Scholar 

  13. Tarsy D, Gordon L 2012 Clinical diagnostic criteria for Parkinson’s disease. In: Parkinson’s disease. CRC Press, 732–741

  14. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601

    Article  Google Scholar 

  15. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Neurosurgery, Psychiatry. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184

    Article  CAS  Google Scholar 

  16. El-Mewafy ZMH, Razek A, El-Eshmawy MM, El-Eneen NRA, El-Biaomy AAB (2018) Magnetic resonance spectroscopy of the frontal region in patients with metabolic syndrome: correlation with anthropometric measurement. Pol J Radiol 83:e215–e219

    Article  Google Scholar 

  17. El-Serougy L, Abdel Razek AA, Ezzat A, Eldawoody H, El-Morsy A (2016) Assessment of diffusion tensor imaging metrics in differentiating low-grade from high-grade gliomas. Neuroradiol J 29(5):400–407

    Article  Google Scholar 

  18. Razek AA, Elmongy A, Hazem M, Zakareyia S, Gabr W (2011) Idiopathic Parkinson disease effect of levodopa on apparent diffusion coefficient value of the brain. Acad Radiol 18(1):70–73

    Article  Google Scholar 

  19. Sasaki M, Shibata E, Kudo K, Tohyama K (2008) Neuromelanin-sensitive MRI. Clin Neuroradiol 18(3):147–153

    Article  Google Scholar 

  20. Xing Y, Sapuan A, Dineen RA, Auer DP (2018) Life span pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI. Mov Disord 33(11):1792–1799

    Article  CAS  Google Scholar 

  21. Kostic VS, Agosta F, Petrovic I, Galantucci S, Spica V, Jecmenica-Lukic M, Filippi M (2010) Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology 75(10):857–863

    Article  CAS  Google Scholar 

  22. Nakamura K, Sugaya K (2014) Neuromelanin-sensitive magnetic resonance imaging: a promising technique for depicting tissue characteristics containing neuromelanin. Neural Regen Res 9(7):759–760

    Article  Google Scholar 

  23. Hashido T, Saito S (2016) Quantitative T1, T2, and T2* mapping and semi-quantitative neuromelanin-sensitive magnetic resonance imaging of the human midbrain. PLoS One 11(10):e0165160

    Article  Google Scholar 

  24. Matsuura K, Maeda M, Yata K, Ichiba Y, Yamaguchi T, Kanamaru K, Tomimoto H (2013) Neuromelanin magnetic resonance imaging in Parkinson’s disease and multiple system atrophy. Eur Neurol 70(1–2):70–77

    Article  CAS  Google Scholar 

  25. Prasad S, Stezin A, Lenka A, George L, Saini J, Yadav R, Pal PK (2018) Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson’s disease. Eur J Neurol 25(4):680–686

    Article  CAS  Google Scholar 

  26. Schwarz ST, Xing Y, Tomar P, Bajaj N, Auer DP (2017) In vivo assessment of brainstem depigmentation in Parkinson disease: potential as a severity marker for multicenter studies. Radiology 283(3):789–798

    Article  Google Scholar 

  27. Kiebish MA, Narain NR (2019) Enabling biomarker discovery in Parkinson’s disease using multiomics: challenges, promise and the future. Per Med 16(1):5–7

    Article  CAS  Google Scholar 

  28. Zhang X, Gao F, Wang D, Li C, Fu Y, He W, Zhang J (2018) Tau pathology in Parkinson’s disease. Front Neurol 9:809

    Article  Google Scholar 

  29. Baquet ZC, Williams D, Brody J, Smeyne RJ (2009) A comparison of model-based (2D) and design-based (3D) stereological methods for estimating cell number in the substantia nigra pars compacta (SNpc) of the C57BL/6J mouse. Neuroscience 161(4):1082–1090

    Article  CAS  Google Scholar 

  30. Yang J, Burciu RG, Vaillancourt DE (2018) Longitudinal progression markers of Parkinson’s disease: current view on structural imaging. Curr Neurol Neurosci Rep 18(12):83

    Article  Google Scholar 

  31. Knorle R (2018) Neuromelanin in Parkinson’s disease: from Fenton reaction to calcium signaling. Neurotox Res 33(2):515–522

    Article  Google Scholar 

  32. Matsuura K, Maeda M, Tabei KI, Umino M, Kajikawa H, Satoh M, Kida H, Tomimoto H (2016) A longitudinal study of neuromelanin-sensitive magnetic resonance imaging in Parkinson’s disease. Neurosci Lett 633:112–117

    Article  CAS  Google Scholar 

  33. Ohtsuka C, Sasaki M, Konno K, Koide M, Kato K, Takahashi J, Takahashi S, Kudo K, Yamashita F, Terayama Y (2013) Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson’s disease using neuromelanin-sensitive MR imaging. Neurosci Lett 541:93–98

    Article  CAS  Google Scholar 

  34. Reimao S, Pita Lobo P, Neutel D et al (2015) Quantitative analysis versus visual assessment of neuromelanin MR imaging for the diagnosis of Parkinson’s disease. J Park Dis 5(3):561–567

    CAS  Google Scholar 

  35. Castellanos G, Fernandez-Seara MA, Lorenzo-Betancor O et al (2015) Automated neuromelanin imaging as a diagnostic biomarker for Parkinson’s disease. Mov Disord 30(7):945–952

    Article  Google Scholar 

  36. Takahashi H, Watanabe Y, Tanaka H et al (2018) Quantifying changes in nigrosomes using quantitative susceptibility mapping and neuromelanin imaging for the diagnosis of early-stage Parkinson’s disease. Br J Radiol 91(1086):20180037

    Article  Google Scholar 

  37. Isaias IU, Trujillo P, Summers P et al (2016) Neuromelanin imaging and dopaminergic loss in Parkinson’s disease. Front Aging Neurosci 8:196

    Article  Google Scholar 

  38. Ogisu K, Kudo K, Sasaki M, Sakushima K, Yabe I, Sasaki H, Terae S, Nakanishi M, Shirato H (2013) 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson’s disease. Neuroradiology 55(6):719–724

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Panzhihua Central Hospital, No. 34 Yikang Street, Panzhihua City, 617067, Sichuan Province, People’s Republic of China

    Xiangming Wang, Yuehui Zhang, Chen Zhu, Guangzong Li, Jie Kang, Fang Chen & Ling Yang

Authors
  1. Xiangming Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuehui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chen Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guangzong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jie Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ling Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ling Yang.

Ethics declarations

The study was based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The searched documents are gradually screened from the title, abstract, and full text according to the pre-set inclusion exclusion criteria. The two researchers conducted the same discussion at the same time. When there is controversy, it should be judged by the third researcher.

Conflict of interests

The authors declare they have no conflict of interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original version of this article was revised: The above article was published online with incorrect author name. The right spelling should be Xiangming Wang instead of Xiangmin Wang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, X., Zhang, Y., Zhu, C. et al. The diagnostic value of SNpc using NM-MRI in Parkinson’s disease: meta-analysis. Neurol Sci 40, 2479–2489 (2019). https://doi.org/10.1007/s10072-019-04014-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-019-04014-y

Keywords

Search

Navigation